Vera Therapeutics, Inc.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a clinical-stage biotechnology company developing treatments for serious immunological diseases, with a focus on autoimmune kidney conditions. Its lead product candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, signaling proteins involved in B-cell… From the company’s description.
In fiscal 2025, Vera Therapeutics, Inc. reported a net loss of $299.62M. Operations used $241.10M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vera Therapeutics, Inc. does
In the company’s own words
Vera Therapeutics, Inc. (Nasdaq: VERA) is a clinical-stage biotechnology company developing treatments for serious immunological diseases, with a focus on autoimmune kidney conditions. Its lead product candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, signaling proteins involved in B-cell activity and autoantibody production. The company is developing atacicept for immunoglobulin A nephropathy (IgAN) and evaluating it in other autoimmune kidney diseases, including primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease. Vera submitted a U.S. biologics license application for atacicept in IgAN in November 2025; the candidate is not yet approved for commercial sale. Its pipeline also includes MAU868, a monoclonal antibody being developed for reactivated BK virus infections in kidney transplant recipients, and VT-109, a preclinical dual BAFF/APRIL inhibitor for B-cell-mediated diseases. Vera holds worldwide development and commercial rights to its candidates through licensing agreements. The company reports its operations as a single business focused on developing and commercializing treatments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1831828
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vera Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vera Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vera Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vera Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vera Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”